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Abstract. Background/Aim: The comparative effects of
daunorubicin, and its new formamidine derivatives containing
either a morpholine moiety (DAUFmor) or a hexamethyle-
neimine moiety (DAUFhex) in the amidine group, on induction
of programmed cell death were determined. Materials and
Methods: The experiments were performed on human acute
lymphoblastic leukemia MOLT-4 cells and human acute
myeloblastic leukemia ML-1 cells. The research was
conducted using the flow cytometry annexin V–fluorescein
(FITC)/propidium iodide (PI) method and tetramethylrho-
damine ethyl ester (TMRE) assay. Results: The various
patterns of temporary changes of early apoptotic cells, late
apoptotic and necrotic cells, and in the frequency of the acute
leukemia cells with high values of mitochondrial membrane
potential (MMP) were found. Phosphatidylserine
externalization, plasma membrane disruption, and changes in
MMP occurring in the leukemia cells were dependent on the
agent tested, its concentration, the time intervals after
daunorubicin, DAUFmor, and DAUFhex application, and on
the leukemia cell line used. Conclusion: The structural
modifications of daunorubicin producing two new analogs,
DAUFmor and DAUFhex, induced the different responses of
MOLT-4 and ML-1 cells to triggering of programmed death.
Daunorubicin, an anthracycline antibiotic, is widely used in
anticancer therapy (1, 2). Nevertheless, its clinical efficacy is
limited by cardiotoxicity and cellular drug resistance (3). In
the search for new derivatives of daunorubicin with
advantageous biological properties, a series of analogs have
been synthesized (4, 5). The transformation of the amino
group at position 3’of the daunosamine moiety into a
formamidino group (-N=CH-N<) (Figure 1) resulted in a
series of new derivatives with different anticancer activity
compared to that of daunorubicin (6, 7). It is accepted that
anticancer potential is dependent on the effective induction of
programmed cell death in cancer cells. However, to our
knowledge, there are no published data on induction of
programmed cell death by formamidinodaunorubicins
containing either a morpholine moiety (DAUFmor) or
hexamethyleneimine moiety (DAUFhex) in the amidine group.
Apoptosis and necrosis are two major types of programmed
cell death (8-10). Changes in the cell membrane are one of the
events occurring during apoptotic and necrotic cell death. It is
known that loss of phospholipid asymmetry leading to
exposure of phosphatidylserine on the outside of the plasma
membrane is an early event of apoptosis (11). Moreover, the
integrity of plasma membrane is compromised during a late
stage of apoptosis and throughout necrosis. Combination
staining with fluorescein (FITC)–conjugated annexin V and
propidium iodide (PI) allows for the identification of early
apoptotic cells, late apoptotic and necrotic cells (12).
Mitochondria play a pivotal role in the regulation of
programmed cell death (13, 14). The mitochondrial membrane
potential (MMP) is a key indicator of cell viability and death.
Changes in MMP directly reflect on cell transition from life
to death (15, 16). The MMP plays an important role in
maintaining the physiological function of the respiratory chain
generating ATP (13). The ATP level is a main determinant of
whether apoptotic or necrotic cell death occurs (17-19). Thus,
evaluation of the MMP is of critical importance for the
assessment of apoptosis and necrosis.
The aim of the present study was to determine and compare
the in vitro influence of the parent compound daunorubicin
and its two analogs DAUFmor, and DAUFhex on human acute
lymphoblastic leukemia MOLT-4 cells and human acute
myeloblastic leukemia ML-1 cells. The effects of these
compounds on triggering phosphatidylserine externalization,
plasma membrane disruption, and changes in MMP in the
leukemia cells were analyzed.
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Materials and Methods
Cells. Human acute lymphoblastic leukemia MOLT-4 cells and
human acute myeloblastic leukemia ML-1 cells were obtained from
the European Collection of Cell Cultures (European Collection of
Cell Cultures, Salisbury, Wiltshire, UK). MOLT-4 and ML-1 cells
were cultured in RPMI 1640 medium (Gibco BRL Life Technologies,
Warsaw, Poland) supplemented with 10% fetal calf serum (Gibco
BRL Life Technologies), 2 mM L-glutamine (Sigma Aldrich, Poznań,
Poland), and antibiotic antimycotic solution (Sigma Aldrich)
containing 20 units of penicillin, 20 μg streptomycin and 0.05 μg
amphotericin B. Every third day, the acute leukemia cells were
passaged. The cells were grown at 37˚C in an atmosphere of 5% CO2
in air (HERAcell incubator; KendroLab, Warsaw, Poland). 
Chemicals. Daunorubicin and its two analogs, DAUFmor and
DAUFhex, were synthesized (20, 21) at the Institute of
Biotechnology and Antibiotics (Warsaw, Poland). The anthracycline
compounds were dissolved in “aqua pro injectione” (Polpharma,
Starogard Gdański, Poland). Stock solutions of these agents at a
concentration of 0.5 mM were stored in the dark at −20˚C. All
solutions were prepared directly before treatment of the MOLT-4
and ML-1 cells. 
Anthracycline doses and cell treatment. After a dilution of the cell
suspension to a density of 15×104 cells/ml medium, MOLT-4 and
ML-1 cells were treated with anthracycline agents. MOLT-4 cells
were exposed to the action of daunorubicin, DAUFmor, and
DAUFhex, at concentrations of 25, 50 and 75 nM, and ML-1 cells
were treated with these agents, at the concentrations of 75 nM,
150 nM, and 225 nM (7). The control consisted of untreated
MOLT-4 and ML-1 cells.
Analyses of leukemia cells after the anthracycline application.
Temporary changes occurring in MOLT-4 and ML-1 cells were
recorded at 24 h, 48 h, and 72 h after exposure to anthracyclines. At
these three time points, plasma membrane diversity and impairment,
and MMP changes were analyzed.
Flow cytometric annexin V-FITC/PI assay. The cell surface exposure
of phosphatidylserine and the plasma membrane impairment of cells
were assessed using Annexin V–FITC Apoptosis Detection Kit
(Calbiochem Merck Millipore, Warsaw, Poland). By staining cells
with a combination annexin V–FITC and PI, it was possible to
identify non-apoptotic live cells (annexin V–FITC–negative/
PI–negative), early apoptotic cells (annexin V–FITC–
positive/PI–negative), and late apoptotic and necrotic cells (annexin
V–FITC–positive/PI–positive) (12). The procedure of dual staining of
cells with annexin V–FITC and PI was performed according to the
manufacturer’s instruction (Calbiochem Merck Millipore). Briefly,
suspension of treated/control leukemia cells, containing 5x105 cells,
were washed with PBS (BioMed, Lublin, Poland) and resuspended in
0.5 ml cold binding buffer. Then 1.25 μl of annexin V–FITC was
added and the cells were incubated in the dark for 15 min at room
temperature. Following incubation, the cells were centrifuged at 
100 ×g for 5 min and the supernatant was removed. The cell pellet
was resuspended in 0.5 ml cold binding buffer, and 10 μl of the 30
μg/ml PI solution was added. Cell samples were placed on ice, away
from light, and FITC and PI fluorescence was immediately measured
using FACSCalibur flow cytometer (Becton Dickinson, New Jersey,
USA). Data were analyzed using CellQuest Pro software (Becton
Dickinson). The frequency of live cells, early apoptotic cells, late
apoptotic and necrotic cells was determined. 
Analysis of mitochondrial membrane potential. MMP was analyzed by
means of the lipophilic cationic dye tetramethylrhodamine ethyl ester
perchlorate (TMRE; Sigma Aldrich). TMRE will accumulate within
mitochondria in inverse proportion to the MMP according to the Nernst
equation. More greatly polarized mitochondria accumulate more cationic
dye, whereas depolarized mitochondria accumulate less dye (22).
A TMRE stock solution was prepared at a concentration of 10 mM
in dimethyl sulfoxide (Sigma Aldrich) and stored at −20˚C. The final
concentration of TMRE staining solution used was 100 nM. The
suspension of treated/control leukemia cells was washed twice in
Hank’s balanced salt solution (HBSS; Gibco Life Technologies),
resuspended in 100 μl of 100 nM TMRE, and incubated for 20 min at
37˚C in the dark. The cells were then washed twice with HBSS, and
finally resuspended in a total volume of 0.5 ml HBSS. TMRE
fluorescence was detected by FACSCalibur flow cytometer (Becton
Dickinson). Data were analyzed using the CellQuest Pro software
(Becton Dickinson).
Statistical evaluation. All experiments were repeated three times with
duplicate or triplicate determinations. All the data are presented as the
mean values±standard deviation. Statistical analyses were performed
using STATISTICA 10 (StatSoft, Cracow, Poland). Data were
analyzed by one-way analysis of variance (ANOVA) followed by
Tukey’s honestly significant difference (HSD) multiple range test. A
difference with p<0.05 was considered statistically significant. 
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Figure 1. Chemical structures of daunorubicin (DAU) and its new
derivatives containing either a morpholine moiety (DAUFmor) or a
hexamethyleneimine moiety (DAUFhex) in the amidine group.
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Figure 2. Effects of daunorubicin (DAU), and its new derivatives containing either a morpholine moiety (DAUFmor) or a hexamethyleneimine moiety
(DAUFhex) in the amidine group, on induction of apoptosis and necrosis in MOLT-4 and ML-1 cells. Representative dot plots for MOLT-4 cells (A)
and ML-1 cells (B): i - apoptotic cells, ii - late apoptotic and necrotic cells, iii - live cells. The frequency of early apoptotic, late apoptotic and
necrotic, and live MOLT-4 (C) and ML-1 cells (D). Values not significantly different at p<0.05 according to the Tukey’s multiple range test: , ,
 between the groups of leukemia cells treated with the anthracycline agents; # compared to controls; + between the time points.
Results 
The influence of daunorubicin and its two analogs DAUFmor
and DAUFhex on alterations in the frequency of MOLT-4
(Figure 2A, 2C) and ML-1 (Figure 2B, 2D) cells undergoing
early apoptosis, late apoptosis and necrosis (Figure 2) and the
frequency of the leukemia MOLT-4 (Figure 3A) and ML-1
(Figure 3B) cells expressing the high values of MMP (Figure
3) were determined. 
Daunorubicin induced apoptotic and necrotic death of
human leukemia cells, and affected their MMP to a higher
degree than did its analogs DAUFmor and DAUFhex.
Moreover, among the daunorubicin derivatives, DAUFmor
appeared to be more active in cell death induction and
reduction of MMP in ML-1 cells than did DAUFhex.
Differences between the effects of DAUFmor and DAUFhex
on apoptosis and necrosis, and the loss of MMP triggered in
MOLT-4 cells were not found.
MOLT-4 cells were more sensitive than ML-1 cells to
triggering programmed cell death. A greater time- and
concentration-dependent decrease of the frequency of cells
with high MMP was observed in MOLT-4 cells than ML-1
cells. Throughout the 72 h period after agent application, a
distinctly higher frequency of late apoptotic and necrotic
MOLT-4 cells was found than ML-1 cells. 
Taking into consideration the results obtained, we can
generally state that the patterns of changes in early apoptosis,
late apoptosis and necrosis, and in the change of MMP
depended on the agent tested, its concentration, the time
intervals of anthracycline application, and the leukemia cell
line used. 
Discussion
In the present study, the effects of daunorubicin, and two
new analogs were determined. It was demonstrated that the
parent anthracycline antibiotic DAU, and the two
formamidinodaunorubicins, DAUFmor and DAUFhex, in
varying degree caused phosphatidylserine externalization,
plasma membrane impairment, and changes of MMP in
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Figure 3. Effects of daunorubicin (DAU), and its new derivatives containing either a morpholine moiety (DAUFmor) or a hexamethyleneimine moiety
(DAUFhex) in the amidine group, on the mitochondrial membrane potential (MMP). Representative dot plots showing MOLT-4 cells (A) and ML-1
cells (B) with the high (R1) and low (R2) MMP values. The frequency of MOLT-4 (A) and ML-1 cells (B) with the high MMP values. Values not
significantly different at p<0.05 according to the Tukey’s multiple range test: , ,  between the groups of leukemia cells treated with the
anthracycline agents; # compared to controls; + between the time points.
MOLT-4 and ML-1 cells. Moreover, it was found that
mitochondria were involved in the leukemia cell response to
the action of these agents. These are the first data showing
that the formamidinodaunorubicin agents trigger
programmed cell death of leukemia cells, and comparing
their cell death-inducing potential. 
The structural modifications of daunorubicin would seem
to be responsible for the different antileukemic activities of the
two new formamidinodaunorubicins. DAUFmor and DAUFhex
differ in the size of the cyclic amine ring in the amidine group.
DAUFmor contains a six-membered morpholine ring with an
oxygen heteroatom in the γ-position in the formamidine group,
while DAUFhex contains a seven-membered hexamethyle-
neimine ring with a CH2 group in the γ position. The
DAUFmor molecule has an oxygen atom, whereas DAUFhex
has two CH2 groups. DAUFmor is capable of forming an
additional hydrogen bond with proton-donating sites, due to the
presence of the free electron pairs on the oxygen atom. These
differences in the molecular structure of the two
formamidinodaunorubicin agents, DAUFmor and DAUFhex,
surely reflect their different biological properties (4-7).
It is accepted that programmed cell death induction is one
mechanism of anticancer therapy (23). However, the
relationship between the efficacy of chemotherapy and
programmed cell death induction is still an open issue. An
understanding of the precise mechanisms of triggering of
programmed cell death by new anthracycline derivatives is
essential for the development of novel anticancer therapeutic
strategies (3).
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